BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 19, 2025
See today's BioWorld Science
Home
» Cancer Research Technology and Merck KGaA patent YAP1/TEAD interaction inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Cancer Research Technology and Merck KGaA patent YAP1/TEAD interaction inhibitors
May 24, 2023
No Comments
Cancer Research Technology Ltd. and Merck KGaA have jointly patented tricyclic heterocycles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors.
BioWorld Science
Cancer
Patents
